- Philstar.com
- The Philippine Star
- Pilipino Star Ngayon
- The Freeman
- Pang-Masa
- Banat
- Interaksyon
- Coupons
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 833899 [Title] => Novartis cancer drug gets Phl FDA approval [Summary] =>The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
[DatePublished] => 2012-08-02 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 731565 [Title] => Treatment for advanced ovarian cancer receives positive opinion [Summary] =>BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
[DatePublished] => 2011-09-29 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 568687 [Title] => Roche's lung cancer drug receives positive opinion in Europe [Summary] =>Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy.
[DatePublished] => 2010-04-23 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => 1475655 [AuthorName] => LPM [SectionName] => Cebu News [SectionUrl] => cebu-news [URL] => ) [3] => Array ( [ArticleID] => 302759 [Title] => Exubera gets positive opinion from EMEA [Summary] => PARIS Sanofi-aventis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of Exubera (insulin human), an inhalable form of insulin, for the treatment of type 1 and type 2 diabetes.
[DatePublished] => 2005-10-20 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
HUMAN USE
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 833899 [Title] => Novartis cancer drug gets Phl FDA approval [Summary] =>The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
[DatePublished] => 2012-08-02 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 731565 [Title] => Treatment for advanced ovarian cancer receives positive opinion [Summary] =>BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
[DatePublished] => 2011-09-29 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 568687 [Title] => Roche's lung cancer drug receives positive opinion in Europe [Summary] =>Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy.
[DatePublished] => 2010-04-23 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => 1475655 [AuthorName] => LPM [SectionName] => Cebu News [SectionUrl] => cebu-news [URL] => ) [3] => Array ( [ArticleID] => 302759 [Title] => Exubera gets positive opinion from EMEA [Summary] => PARIS Sanofi-aventis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of Exubera (insulin human), an inhalable form of insulin, for the treatment of type 1 and type 2 diabetes.
[DatePublished] => 2005-10-20 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
EZ2 - 12 21
SUERTRES - 2 1 3
6D Lotto - 7 5 9 3 0 1
6/42 Lotto - 5 26 2 21 8 27
P19,033,913.00
6/49 Super Lotto - 32n 24 38 35 15
P62,95,035.00
- 12:00 am